Literature DB >> 14701740

Phosphorylation of C/EBPalpha inhibits granulopoiesis.

Sarah E Ross1, Hanna S Radomska, Bo Wu, Pu Zhang, Jonathon N Winnay, Laszlo Bajnok, Wendy S Wright, Fred Schaufele, Daniel G Tenen, Ormond A MacDougald.   

Abstract

CCAAT/enhancer-binding protein alpha (C/EBPalpha) is one of the key transcription factors that mediate lineage specification and differentiation of multipotent myeloid progenitors into mature granulocytes. Although C/EBPalpha is known to induce granulopoiesis while suppressing monocyte differentiation, it is unclear how C/EBPalpha regulates this cell fate choice at the mechanistic level. Here we report that inducers of monocyte differentiation inhibit the alternate cell fate choice, that of granulopoiesis, through inhibition of C/EBPalpha. This inhibition is mediated by extracellular signal-regulated kinases 1 and/or 2 (ERK1/2), which interact with C/EBPalpha through an FXFP docking site and phosphorylate serine 21. As a consequence of C/EBPalpha phosphorylation, induction of granulocyte differentiation by C/EBPalpha or retinoic acid is inhibited. Our analysis of C/EBPalpha by fluorescent resonance energy transfer revealed that phosphorylation induces conformational changes in C/EBPalpha, increasing the distance between the amino termini of C/EBPalpha dimers. Thus, myeloid development is partly regulated by an ERK1/2-mediated change in the conformation of C/EBPalpha that favors monocyte differentiation by blocking granulopoiesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14701740      PMCID: PMC343788          DOI: 10.1128/MCB.24.2.675-686.2004

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  56 in total

1.  Phosphorylation of the kinase suppressor of ras by associated kinases.

Authors:  D J Volle; J A Fulton; O V Chaika; K McDermott; H Huang; L A Steinke; R E Lewis
Journal:  Biochemistry       Date:  1999-04-20       Impact factor: 3.162

2.  p300 coactivates the adipogenic transcription factor CCAAT/enhancer-binding protein alpha.

Authors:  R L Erickson; N Hemati; S E Ross; O A MacDougald
Journal:  J Biol Chem       Date:  2001-05-11       Impact factor: 5.157

3.  Förster distances between green fluorescent protein pairs.

Authors:  G H Patterson; D W Piston; B G Barisas
Journal:  Anal Biochem       Date:  2000-09-10       Impact factor: 3.365

4.  Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

Authors:  T Pabst; B U Mueller; P Zhang; H S Radomska; S Narravula; S Schnittger; G Behre; W Hiddemann; D G Tenen
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

5.  C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts.

Authors:  X Wang; E Scott; C L Sawyers; A D Friedman
Journal:  Blood       Date:  1999-07-15       Impact factor: 22.113

6.  The structure of a CREB bZIP.somatostatin CRE complex reveals the basis for selective dimerization and divalent cation-enhanced DNA binding.

Authors:  M A Schumacher; R H Goodman; R G Brennan
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

7.  Glycogen synthase kinase 3 is an insulin-regulated C/EBPalpha kinase.

Authors:  S E Ross; R L Erickson; N Hemati; O A MacDougald
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

8.  C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription.

Authors:  B A Slomiany; K L D'Arigo; M M Kelly; D T Kurtz
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 9.  Molecular regulation of adipogenesis.

Authors:  E D Rosen; B M Spiegelman
Journal:  Annu Rev Cell Dev Biol       Date:  2000       Impact factor: 13.827

10.  AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Authors:  T Pabst; B U Mueller; N Harakawa; C Schoch; T Haferlach; G Behre; W Hiddemann; D E Zhang; D G Tenen
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

View more
  58 in total

1.  C/EBPα and DEK coordinately regulate myeloid differentiation.

Authors:  Rositsa I Koleva; Scott B Ficarro; Hanna S Radomska; Marlene J Carrasco-Alfonso; John A Alberta; James T Webber; C John Luckey; Guido Marcucci; Daniel G Tenen; Jarrod A Marto
Journal:  Blood       Date:  2012-04-03       Impact factor: 22.113

2.  Regulation of cathelicidin antimicrobial peptide expression by an endoplasmic reticulum (ER) stress signaling, vitamin D receptor-independent pathway.

Authors:  Kyungho Park; Peter M Elias; Yuko Oda; Donald Mackenzie; Theodora Mauro; Walter M Holleran; Yoshikazu Uchida
Journal:  J Biol Chem       Date:  2011-08-08       Impact factor: 5.157

3.  The molecular scaffold kinase suppressor of Ras 1 (KSR1) regulates adipogenesis.

Authors:  Robert L Kortum; Diane L Costanzo; Jamie Haferbier; Steven J Schreiner; Gina L Razidlo; Ming-Hoi Wu; Deanna J Volle; Toshiyuki Mori; Hiroshi Sakaue; Nina V Chaika; Oleg V Chaika; Robert E Lewis
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

4.  C/EBPalpha directs monocytic commitment of primary myeloid progenitors.

Authors:  Dehua Wang; Jenice D'Costa; Curt I Civin; Alan D Friedman
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

Review 5.  Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Authors:  Daniel E Johnson
Journal:  Adv Enzyme Regul       Date:  2007-11-19

Review 6.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

7.  Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Authors:  Il-Kyoo Park; Anjali Mishra; Jason Chandler; Susan P Whitman; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

8.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

9.  Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.

Authors:  Karl Staser; Su-Jung Park; Steven D Rhodes; Yi Zeng; Yong Zheng He; Matthew A Shew; Jeffrey R Gehlhausen; Donna Cerabona; Keshav Menon; Shi Chen; Zejin Sun; Jin Yuan; David A Ingram; Grzegorz Nalepa; Feng-Chun Yang; D Wade Clapp
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

10.  The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.

Authors:  Daniel Helbling; Beatrice U Mueller; Nikolai A Timchenko; Anne Hagemeijer; Martine Jotterand; Sandrine Meyer-Monard; Andrew Lister; Janet D Rowley; Barbara Huegli; Martin F Fey; Thomas Pabst
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.